Welcome to LookChem.com Sign In|Join Free

CAS

  • or

6000-44-8

Post Buying Request

6000-44-8 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

6000-44-8 Usage

Description

Sodium glycinate is a non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.

Chemical Properties

White or light yellow crystalline powder. Hygroscopic, easily soluble in water.

Uses

Sodum glycinate is a useful research chemical. It Inhibits spinal cord neurotransmitter, allosteric regulator of NMDA receptors.

Check Digit Verification of cas no

The CAS Registry Mumber 6000-44-8 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,0,0 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 6000-44:
(6*6)+(5*0)+(4*0)+(3*0)+(2*4)+(1*4)=48
48 % 10 = 8
So 6000-44-8 is a valid CAS Registry Number.
InChI:InChI=1/C16H24FNO/c1-3-15(2)12-16(8-10-18,9-11-19-15)13-4-6-14(17)7-5-13/h4-7H,3,8-12,18H2,1-2H3

6000-44-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name SODIUM GLYCINATE

1.2 Other means of identification

Product number -
Other names sodium,2-aminoacetate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:6000-44-8 SDS

6000-44-8Relevant articles and documents

Study on the Structure of Cu/ZrO2 Catalyst and the Formation Mechanism of Disodium Iminodiacetate and Sodium Glycine

Wang, Yongsheng,Zhu, Hongwen,Duan, Zhengkang,Zhao, Zhenzhen,Zhao, Yunlu,Lan, Xiaolin,Chen, Li,Guo, Dongjie

, p. 1111 - 1120 (2020)

Abstract: A new method to prepare Cu/ZrO2 catalysts by reducing CuO/ZrO2 with hydrazine hydrate is reported, and the prepared catalysts were used to synthesize disodium iminodiacetate by diethanolamine dehydrogenation. Hydrazine hydrate can rapidly reduce the CuO/ZrO2 precursor powder in an alkaline environment at a moderate temperature. The ratio of Cu0/Cu+ at the Cu/ZrO2 surface was controlled by the amount of hydrazine hydrate and the reduction reaction time. The formation mechanism of disodium glycine as the main byproduct and iminodiacetate were deduced by investigating the product yield, the reaction time, and the presence of acetaldehyde in the evolved gas. It has been shown that the ratio of Cu0/Cu+ in Cu/ZrO2 significantly affects the dehydrogenation of diethanolamine into disodium iminodiacetate. Cu0 and Cu+ are the catalytic activity centers in the dehydrogenation of diethanolamine which respectively produce intermediate aldehydes and an ester via nucleophilic addition reactions. The formation mechanism of sodium glycinate is related to the tautomerism of intermediate products and Schiff base hydrolysis. Graphic Abstract: The formation mechanism of disodium iminodiacetate and sodium glycine producing by the dehydrogenation of diethanolamine over the Cu/ZrO2 catalysts which were prepared by a new reduction method.

Synthesis, characterization, DNA and HSA binding studies of isomeric Pd (II) antitumor complexes using spectrophotometry techniques

Zareian-Jahromi, Sareh,Mansouri-Torshizi, Hassan

, p. 1329 - 1350 (2017/09/30)

Two new Palladium(II) isomeric complexes, [Pd (Gly)(Leu)](I) and [Pd (Gly)(Ile)](II), where Gly is glycine, and Leu and Ile are isomeric amino acids (leucine and isoleucine), have been synthesized and characterized by elemental analysis, molar conductivity measurements, FT-IR, 1H NMR, and UV–Vis. The complexes have been tested for their In vitro cytotoxicity against cancer cell line K562 and their binding properties to calf thymus DNA (CT-DNA) and human serum albumin (HSA) have also been investigated by multispectroscopic techniques. Interactions of these complexes with CT-DNA were monitored using gel electrophoresis. The energy transfer from HSA to these complexes and the binding distance between HSA and the complexes (r) were calculated. The results obtained from these studies indicated that at very low concentrations, both complexes effectively interact with CT-DNA and HSA. Fluorescence studies revealed that the complexes strongly quench DNA bound ethidium bromide as well as the intrinsic fluorescence of HSA through the static quenching procedures. Binding constant (Kb), apparent biomolecular quenching constant (kq), and number of binding sites (n) for CT-DNA and HSA were calculated using Stern–Volmer equation. The calculated thermodynamic parameters indicated that the hydrogen binding and vander Waals forces might play a major role in the interaction of these complexes with HSA and DNA. Thus, we propose that the complexes exhibit the groove binding with CT-DNA and interact with the main binding pocket of HSA. The complexes follow the binding affinity order of I?>?II with DNA- and II?>?I with HSA-binding.

RUTHENIUM COMPLEXES AND THEIR USES AS CATALYSTS IN PROCESSES FOR FORMATION AND/OR HYDROGENATION OF ESTERS, AMIDES AND RELATED REACTIONS

-

Paragraph 0291; 0326, (2017/10/18)

The present invention relates to novel Ruthenium complexes of formulae A1-A4 and their use, inter alia, for (1) dehydrogenative coupling of alcohols to esters; (2) hydrogenation of esters to alcohols (including hydrogenation of cyclic esters (lactones) or cyclic di-esters (di-lactones), or polyesters); (3) preparing amides from alcohols and amines—(including the preparation of polyamides (e.g., polypeptides) by reacting dialcohols and diamines and/or polymerization of amino alcohols and/or forming cyclic dipeptides from p-aminoalcohols; (4) hydrogenation of amides (including cyclic dipeptides, polypeptides and polyamides) to alcohols and amines; (5) hydrogenation of organic carbonates (including polycarbonates) to alcohols or hydrogenation of carbamates (including polycarbamates) or urea derivatives to alcohols and amines; (6) dehydrogenation of secondary alcohols to ketones; (7) amidation of esters (i.e., synthesis of amides from esters and amines); (8) acylation of alcohols using esters; (9) coupling of alcohols with water and a base to form carboxylic acids; and (10) preparation of amino acids or their salts by coupling of amino alcohols with water and a base. The present, invention further relates to the use of certain known Ruthenium complexes for the preparation of amino acids or their salts from amino alcohols.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 6000-44-8